The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

Tirzepatide

FDA-approved · Grade A

Goals
weight-loss
Evidence
12 RCT / 35 animal / 20 in vitro
Routes
injectable-sc
WADA
No
FDA
Approved
Cancer caution
none
Typical dose
2.5 mg → titrated to 5/10/15 mg weekly
Half-life
~5 days (~120 hours)
Primary mechanism
GLP-1 receptor agonism
View full report →

Semaglutide

FDA-approved · Grade A

Goals
weight-loss
Evidence
10 RCT / 1 animal / 0 in vitro
Routes
injectable-sc, oral
WADA
No
FDA
Approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
GLP-1 receptor agonism
View full report →

5-Amino-1MQ

Research chemical · Grade C

Goals
muscle, weight-loss, mitochondria
Evidence
0 RCT / 4 animal / 3 in vitro
Routes
oral
WADA
No
FDA
Not approved
Cancer caution
caution
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

AOD-9604

Research chemical · Grade C

Goals
weight-loss, muscle, hormonal
Evidence
6 RCT / 4 animal / 3 in vitro
Routes
injectable-sc
WADA
S2
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →